Episode:33 - Orr Inbar Discusses Saving Costs and Complications With Clinical Trial Simulations

The Scope of Things

In this episode of the Scope of Things, host Deborah Borfitz covers concerns surrounding the study and treatment of obesity, a new “opening doors” initiative to clinical trials, debate over the European Union AI Act, the first international-level clinical study using secure multiparty computation, a hopeful treatment for kids with lethal brain tumors, and a ChatGPT tool created by the NIH to match potential volunteers to relevant studies. Joining the conversation is Orr Inbar, CEO and co-founder of QuantHealth, who discusses how his company is using AI to simulate clinical trials to alleviate costs and efficiency issues for the notoriously complicated drug development process. He also shares the proprietary tech powering QuantHealth’s AI and where he sees AI heading as 2025 unfolds.

News Roundup

Perspectives on the EU AI Act

• Insights about the rollout in Clinical Research News
• Article in Clinical Research News about discussion at SCOPE Europe

Secure multiparty computation

• Article in Bio-IT World
• Study in npj Digital Medicine

Cell therapy for childhood brain cancer

• Study published in Nature
• Stanford Medicine press release

TrialGPT tool

• Study in Nature Communications

The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider’s look at clinical research today.